,address1,city,state,zip,country,phone,fax,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,auditRisk,boardRisk,compensationRisk,shareHolderRightsRisk,overallRisk,governanceEpochDate,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,priceToSalesTrailing12Months,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,sharesShort,sharesShortPriorMonth,sharesShortPreviousMonthDate,dateShortInterest,sharesPercentSharesOut,heldPercentInsiders,heldPercentInstitutions,shortRatio,shortPercentOfFloat,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToRevenue,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,targetHighPrice,targetLowPrice,targetMeanPrice,targetMedianPrice,recommendationMean,recommendationKey,numberOfAnalystOpinions,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,totalRevenue,debtToEquity,revenuePerShare,returnOnAssets,returnOnEquity,grossProfits,freeCashflow,operatingCashflow,revenueGrowth,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Dr. David  Apelian M.B.A., M.D., MBA, Ph.D.', 'age': 57, 'title': 'CEO & Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 204386, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
1,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Dr. Jeffrey S. Glenn M.D., Ph.D.', 'age': 59, 'title': 'Scientific Founder & Independent Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 67000, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
2,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Mr. Eldon C. Mayer III, M.B.A.', 'age': 61, 'title': 'Chief Commercial Officer', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 586963, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
3,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Mr. William G. Kaichoff CPA, CPA', 'age': 56, 'title': 'CFO and Principal Financial & Accounting Officer', 'yearBorn': 1966, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
4,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Mr. Christopher A. Kurtz', 'age': 55, 'title': 'Chief Technical Officer', 'yearBorn': 1967, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
5,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Mr. James  Vollins J.D.', 'age': 53, 'title': 'Gen. Counsel, Chief Compliance Officer & Corp. Sec.', 'yearBorn': 1969, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
6,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Dr. Ingrid C. Choong', 'title': 'Sr. VP of Clinical Devel.', 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
7,2155 Park Boulevard,Palo Alto,CA,94306,United States,650 272 6138,650 618 1621,https://www.eigerbio.com,Biotechnology,Healthcare,"Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.",56,"{'maxAge': 1, 'name': 'Dr. Colin  Hislop M.D., MBBS', 'age': 64, 'title': 'Sr. VP of Clinical & Devel. Operations', 'yearBorn': 1958, 'exercisedValue': 0, 'unexercisedValue': 0}",4,7,10,7,9,1693526400,1672444800,86400,4,0.45,0.4,0.4,0.4473,0.45,0.4,0.4,0.4473,0.0,1.633125,-0.69551724,453970,453970,519135,687720,687720,0.4,0.4228,1100,900,17869168,0.298,8.35,1.1542645,0.7318,1.23755,0.0,0.0,USD,199174,0.0,35321077,44296400,1261178,1198254,1690761600,1693440000,0.028499998,0.1173,0.62347,6.1,0.034,0.345,1.1692754,1672444800,1703980800,1688083200,-95728000,-2.13,-0.58,1:15,1458691200,0.013,-0.002,NGM,EQUITY,EIGR,EIGR,"Eiger BioPharmaceuticals, Inc.","Eiger BioPharmaceuticals, Inc.",1391092200,America/New_York,EDT,-14400000,0.4034,5.0,1.0,3.0,3.0,1.0,strong_buy,3,58341000,1.317,-92798000,40671000,3.713,4.217,15481000,265.91,0.351,-0.49293,-1.61949,11647000,-54912000,-88847000,0.135,0.91059995,0.0,-6.0127897,USD,
